Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
An annual Congress providing a comprehensive overview of all the practice-changing new data. Submit your abstract until 30 January 2019!
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
ESMO Symposium on Signalling Pathways in Cancer 2019 in partnership with the EACR focuses on gene fusions from gene architecture evolution to cell addiction and therapeutic opportunities. ESMO and EACR Co-Chairs, Drs Andrea Sartore-Bianchi and Joan Seoane discuss the relevance of gene fusions in oncology, what to expect from the programme, concept of the sessions, who may benefit from attendance, and why it is important that societies like ESMO and EACR collaborate in such a Symposium. They welcome all delegates from 26 to 27 April 2019 in Barcelona, Spain.
15 Jan 2019
FDA Approves Longer-acting Calaspargase Pegol-mknl for ALL
14 Jan 2019
Online application available for ESMO Preceptorship on Brain Tumours 2019. Join us in Lugano!
14 Jan 2019
EndoPredict, Oncotype DX Breast Recurrence Score and Prosigna are recommended, while MammaPrint and IHC4+C are not
11 Jan 2019
Advanced Breast Cancer - algorithms from the 4th ESO-ESMO International Consensus Guidelines
11 Jan 2019
CD123-directed cytotoxin is indicated in adults and in paediatric patients
10 Jan 2019
For the management of patients with metastatic non-small cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.
Lugano, Switzerland
01 Feb
- 02 Feb
2019
Capetown, South Africa
15 Feb
- 17 Feb
2019
Valencia, Spain
22 Feb
- 22 Feb
2019
Paris, France
25 Feb
- 27 Feb
2019
Manchester, United Kingdom
06 Mar
- 08 Mar
2019
Lugano, Switzerland
08 Mar
- 10 Mar
2019
